European union regulatory developments for new vaccine adjuvants and delivery systems

Vaccine

Volumn 22, Issue 19, 2004, Pages 2452-2456

  Sesardic, Dorothea ^a   Dobbelaer, Roland ^b  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

Delivery systems; New vaccine adjuvants; Regulatory considerations

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; CALCIUM PHOSPHATE; CHITOSAN; COLONY STIMULATING FACTOR 1; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; INTERLEUKIN 2; ISCOM; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; POLYGLACTIN; QS 21; SURFACTANT; VACCINE; VIROSOME;

CONFERENCE PAPER; CPG ISLAND; DRUG DELIVERY SYSTEM; DRUG SAFETY; HUMAN; IMMUNOGENICITY; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG AND NARCOTIC CONTROL; DRUG DELIVERY SYSTEMS; EUROPEAN UNION; HUMANS; VACCINES;

EID: 2942620283     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.11.071     Document Type: Conference Paper

References (12)

1. Sesardic D, Corbel MJ. Pre-clinical evaluation and quality control aspects of microparticulate antigen delivery systems. In: Gander B, Merkle HP, Corradin H, editors. Antigen delivery systems: immunological and technical issues. Harwood Academic Press; 1997. p. 227-50.
2. Schijns V.E.J.C. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 12:2000;456-463
3. Brewer J.M., Conacher M., Satoskar A., Bluethmann H., Alexander J. In IL-4 defficient mice, alum not only generates T-helper-1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper-2 cytokine production. Eur. J. Immunol. 26:1996;2062-2066
4. The European Pharmacopoeia Commission 2002. English fourth ed. General Monograph: Vaccines for Human Use; 2002: 153.
5. Committee for Proprietary Medicinal Products (CPMP) 1998. Note for Guidance on Pharmaceutical and Biological Aspects of Combined Vaccines (CPMP/BWP/447/97). http://www.emea.eu.int.
6. Committee for Proprietary Medicinal Products (CPMP) 1997. Note for Guidance on the Pre-clinical, Pharmaceutical and Toxicological Testing of Vaccines. (CPMP/SWP/465.95). http://www.emea.eu.int.
7. Committee for Proprietary Medicinal Products (CPMP) 1999. Note for Guidance on the Clinical Evaluation on New Vaccines. (CPMP/SWP/463.97). http://www.emea.eu.int.
8. Committee for Proprietary Medicinal Products (CPMP) 2003. Note for Guidance on Requirements for the Evaluation of Adjuvants in Vaccines (EMEA/CPMP/EWP/17/03 - Draft 2).
9. Ehreth J. The global value of vaccination. Vaccine. 21:2003;596-600
10. Baker J.P. The pertussis vaccine controversy in Great Britain, 1974-1986. Vaccine. 21:2003;4003-4010
11. Andre F.E. Vaccinology: past achievements. Vaccine. 21:2003;593-595
12. Chen RT. Safety of vaccines. In: Plotkin SA, Orenstein WA, editors, Vaccines. third ed. Philadelphia: Saunders; 1999.